Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$1.79 - $2.63 $3,343 - $4,912
1,868 New
1,868 $4,000
Q1 2023

May 09, 2023

BUY
$2.74 - $4.44 $241,873 - $391,941
88,275 New
88,275 $265,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $336M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.